Both Semaglutide and Tirzepatide have been extensively studied for safety and are approved for long-term use
Ethical approval Only aggregated counts and statistical summaries of de-identified information without any protected health information are received from participating HCOs, and no study-specific activities are performed in these retrospective analyses
C., Ganesan, M., Osna, N
Combining multiple peptides may increase the risk of side effects, drug interactions and unpredictable hormonal changes, particularly when using unregulated products without medical supervision
However, the risk increases when used with: Signs of hypoglycemia can include shakiness, sweating, rapid heartbeat, hunger, irritability, confusion, or dizziness
See CJC-1295 / Ipamorelin for the complete dual-pathway guide, FAQs, and request flow